Latent tuberculosis infection and interferon-gamma release assays: What new knowledge did we gain through the Journal in 2009?

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 12, 2010, Pages 1525-1529

  Van Der Werf, Marieke J ^a   Van Leth, F ^b  

^a KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON;

ASSAY; DIAGNOSTIC TEST; DISEASE MARKER; INFECTION RISK; INTERMETHOD COMPARISON; LATENT TUBERCULOSIS; PRIORITY JOURNAL; REVIEW; TUBERCULIN TEST;

BIOLOGICAL MARKERS; HUMANS; INTERFERON-GAMMA; LATENT TUBERCULOSIS; RISK; TUBERCULIN TEST;

EID: 78649358130     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Styblo K. The relationship between the risk of tuberculous infection and the risk of developing infectious tuberculosis. Bull Int Union Tuberc 1985; 60: 117-119.
2. van Leth F, van der Werf M J, Borgdorff M W. Prevalence of tuberculous infection and incidence of tuberculosis: a rea ssessment of the Styblo rule. Bull World Health Organ 2008; 86: 20-26.
3. Dye C, Bassili A, Bierrenbach A L, et al. Measuring tuberculosis burden, trends, and the impact of control programmes. Lancet Infect Dis 2008; 8: 233-243.
4. Bachtiar A, Miko T Y, Machmud R, et al. Annual risks of tuberculous infection in East Nusa Tenggara and Central Java Provinces, Indonesia. Int J Tuberc Lung Dis 2009; 13: 32-38.
5. Bachtiar A, Miko T Y, Machmud R, et al. High risk of tuberculous infection in North Sulawesi Province of Indonesia. Int J Tuberc Lung Dis 2009; 13: 1513-1518.
6. Al-Absi A, Bassili A, Abdul Bary H, et al. The decline of tuberculosis in Yemen: evaluation based on two nationwide tuberculin surveys. Int J Tuberc Lung Dis 2009; 13: 1100-1105.
7. Bachtiar A, Miko T Y, Machmud R, et al. Annual risk of tuberculosis infection in West Sumatra Province, Indonesia. Int J Tuberc Lung Dis 2008; 12: 255-261.
8. Shanaube K, Sismanidis C, Ayles H, et al. Annual risk of tuberculous infection using different methods in communities with a high prevalence of TB and HIV in Zambia and South Africa. PLoS ONE 2009; 4: e7749.
9. Egwaga S M, Cobelens F G, Muwinge H, Verhage C, Kalisvaart N, Borgdorff M W. The impact of the HIV epidemic on tuberculosis transmission in Tanzania. AIDS 2006; 20: 915-921.
10. Hanifa Y, Grant A D, Lewis J, Corbett E L, Fielding K, Churchyard G. Prevalence of latent tuberculosis infection among gold miners in South Africa. Int J Tuberc Lung Dis 2009; 13: 39-46.
11. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and nontuberculous mycobacteria? Int J Tuberc Lung Dis 2006; 10: 1192-1204.
12. World Health Organization. Immunization surveillance, assessment and monitoring. Geneva, Switzerland: WHO, 2010. http://www.who.int/immunization- monitoring/en/globalsummary/timeseries/tscoveragebcg.htm. Accessed August 2010.
13. Addo K K, van den Hof S, Mensah G I, et al. A tuberculin skin test survey among Ghanaian school children. BMC Public Health 2010; 10: 35.
14. Kritzinger F E, den Boon S, Verver S, et al. No decrease in annual risk of tuberculosis infection in endemic area in Cape Town, South Africa. Trop Med Int Health 2009; 14: 136-142.
15. Sgountzos V, Simopoulou S, Kretsou S, et al. Comparative study of RT23 and Merieux tuberculin tested among healthy volunteers. Int J Tuberc Lung Dis 2009; 13: 312-316.
16. Blumberg H M, White N, Parrott P, Gordon W, Hunter M, Ray S. False-positive tuberculin skin test results among health care workers. JAMA 2000; 283: 2793.
17. Villarino M E, Burman W, Wang Y C, et al. Comparable specificity of 2 commercial tuberculin reagents in persons at low risk for tuberculous infection. JAMA 1999; 281: 169-171.
18. Lifson A R, Watters J K, Thompson S, Crane C M, Wise F. Discrepancies in tuberculin skin test results with two commercial products in a population of intravenous drug users. J Infect Dis 1993; 168: 1048-1051.
19. Arnadottir T, Rieder H L, Trébucq A, Waaler H T. Guidelines for conducting tuberculin skin test surveys in high prevalence countries. Tubercle Lung Dis 1996; 77 (Suppl 1): S1-S19.
20. del Río Camacho G, Perea-Milla E, Romero González J, Pérez Frías J. Interpretation of a serial Mantoux test taking into account the annual risk of tuberculous infection. Int J Tuberc Lung Dis 2009; 13: 196-200.
21. Vitek E, Gusseinova N, Laricheva N, et al. Factors associated with positive tuberculin skin test results among HIV-infected persons in Orel Oblast, Russia. Int J Tuberc Lung Dis 2009; 13: 829-835.
22. Webb E A, Hesseling A C, Schaaf H S, et al. High prevalence of Mycobacterium tuberculosis infection and disease in children and adolescents with type 1 diabetes mellitus. Int J Tuberc Lung Dis 2009; 13: 868-874.
23. Cobelens F G, Egwaga S M, van Ginkel T, Muwinge H, Matee M I, Borgdorff M W. Tuberculin skin testing in patients with HIV infection: limited benefit of reduced cutoff values. Clin Infect Dis 2006; 43: 634-639.
24. O'Neal S, Hedberg K, Markum A, Schafer S. Discordant tuberculin skin and interferon-gamma tests during contact investigations: a dilemma for tuberculosis controllers. Int J Tuberc Lung Dis 2009; 13: 662-664.
25. Pai M, Dheda K, Cunningham J, Scano F, O'Brien R. T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward. Lancet Infect Dis 2007; 7: 428-438.
26. Pai M, Joshi R, Dogra S, et al. T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. Int J Tuberc Lung Dis 2009; 13: 84-92.
27. van Zyl-Smit R N, Zwerling A, Dheda K, Pai M. Within-s ubject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS ONE 2009; 4: e8517.
28. Burgos J L, Kahn J G, Strathdee S A, et al. Targeted screening and treatment for latent tuberculosis infection using QuantiFERON®-TB Gold is cost-effective in Mexico. Int J Tuberc Lung Dis 2009; 13: 962-968.
29. Garfein R S, Laniado-Laborin R, Rodwell T C, et al. Latent tuberculosis among persons at risk for infection with HIV, Tijuana, Mexico. Emerg Infect Dis 2010; 16: 757-763.
30. Garfein R S, Lozada R, Liu L, et al. High prevalence of latent tuberculosis infection among injection drug users in Tijuana, Mexico. Int J Tuberc Lung Dis 2009; 13: 626-632.
31. Heckathorn D D. Respondent-driven sampling: a new approach to the study of hidden populations. Social Problems 1997; 44: 174-199.
32. Bienek D R, Chang C K. Evaluation of an interferon-gamma release assay, T-SPOT®.TB, in a population with a low prevalence of tuberculosis. Int J Tuberc Lung Dis 2009; 13: 1416-1421.
33. Kunimoto D, Der E, Beckon A, et al. Use of the QuantiFERON®-TB Gold test to confirm latent tuberculosis infection in a Canadian tuberculosis clinic. Int J Tuberc Lung Dis 2009; 13: 726-730.
34. National Institute of Health and Clinical Excellence. Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London, UK: NICE, 2006. http://www.nice.org.uk/nicemedia/pdf/CG033niceguideline. pdf Accessed June 2010.
35. Kik S V, Franken W P J, Arend S M, et al. Interferon-gamma release assays in immigrant contacts and effect of remote exposure to Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009; 13: 820-828.
36. Borgdorff M W, Nagelkerke N J, de Haas P E, van Soolingen D. Transmission of Mycobacterium tuberculosis depending on the age and sex of source cases. Am J Epidemiol 2001; 154: 934-943.
37. Shovman O, Anouk M, Vinnitsky N, et al. QuantiFERON®-TB Gold in the identification of latent tuberculosis infection in rheumatoid arthritis: a pilot study. Int J Tuberc Lung Dis 2009; 13: 1427-1432.
38. Lew W J, Jung Y J, Song J-W, et al. Combined use of QuantiFERON®-TB Gold assay and chest computed tomography in a tuberculosis outbreak. Int J Tuberc Lung Dis 2009; 13: 633-639.
39. Machado A Jr, Finkmoore B, Emodi K, et al. Risk factors for failure to complete a course of latent tuberculosis infection treatment in Salvador, Brazil. Int J Tuberc Lung Dis 2009; 13: 719-725.
40. Torres Costa J, Sa R, Cardoso M J, et al. Tuberculosis screening in Portuguese healthcare workers using the tuberculin skin test and the interferon-gamma release assay. Eur Respir J 2009; 34: 1423-1428.
41. Nienhaus A, Schablon A, Diel R. Interferon-gamma release assay for the diagnosis of latent TB infection - analysis of discordant results, when compared to the tuberculin skin test. PLoS ONE 2008; 3: e2665.
42. Davidow A L. Interferon-gamma release assay test characteristics depend upon the prevalence of active tuberculosis. Int J Tuberc Lung Dis 2009; 13: 1411-1415.
43. Kobashi Y, Mouri K, Yagi S, et al. Clinical evaluation of the QuantiFERON®-TB Gold test in patients with non-tuberculous mycobacterial disease. Int J Tuberc Lung Dis 2009; 13: 1422-1426.
44. Ruhwald M, Ravn P. Biomarkers of latent TB infection. Expert Rev Respir Med 2009; 3: 387-401.
45. Ruhwald M, Bjerregaard-Andersen M, Rabna P, Eugen-Olsen J, Ravn P. IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M. tuberculosis in a whole blood based T-cell assay. BMC Res Notes 2009; 2: 19.
46. Ruhwald M, Bodmer T, Maier C, et al. Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur Respir J 2008; 32: 1607-1615.
47. Lighter J, Rigaud M, Huie M, Peng C-H, Pollack H. Chemokine IP-10: an adjunct marker for latent tuberculosis infection in children. Int J Tuberc Lung Dis 2009; 13: 731-736.
48. Petrucci R, Abu Amer N, Gurgel R Q, et al. Interferon gamma, interferon-gamma-induced-protein 10, and tuberculin responses of children at high risk of tuberculosis infection. Pediatr Infect Dis J 2008; 27: 1073-1077.
49. Ruhwald M, Petersen J, Kofoed K, et al. Improving T-cell a ssays for the diagnosis of latent TB infection: potential of a diagnostic test based on IP-10. PLoS ONE 2008; 3: e2858.